Company Description
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders.
Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.
The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024.
The company was incorporated in 2020 and is based in Alpharetta, Georgia.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Gregory Duncan |
Contact Details
Address: 44 Milton Avenue Alpharetta, Georgia 30009 United States | |
| Phone | 866 620 8655 |
| Website | dwtx.com |
Stock Details
| Ticker Symbol | DWTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001818844 |
| CUSIP Number | 92829J203 |
| ISIN Number | US92829J2033 |
| Employer ID | 85-4314201 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. William L. Pridgen M.D. | Founder and Member of Scientific Advisory Board |
| Angela Walsh | Chief Financial Officer, Secretary and Treasurer |
| Dr. R. Michael Gendreau M.D., Ph.D. | Chief Medical Officer |
| Ralph D. Grosswald M.P.H. | Senior Vice President of Operations |
| Carol Duffy Ph.D. | Chief Scientific Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 26, 2026 | 8-K | Current Report |
| Mar 18, 2026 | 10-K | Annual Report |
| Mar 18, 2026 | 8-K | Current Report |
| Mar 12, 2026 | 8-K | Current Report |
| Feb 13, 2026 | DEF 14A | Other definitive proxy statements |
| Jan 29, 2026 | EFFECT | Notice of Effectiveness |
| Jan 23, 2026 | PRE 14A | Other preliminary proxy statements |
| Jan 20, 2026 | 8-K | Current Report |
| Jan 15, 2026 | S-3 | Registration statement under Securities Act of 1933 |
| Jan 13, 2026 | 8-K | Current Report |